Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The study is being performed to determine whether sitagliptin, a dipeptidyl peptidase-4
inhibitor, both acutely and chronically improves blood vessel function. Patients with type 2
diabetes who are on metformin will be enrolled in this study for up to 22 weeks in this
double blinded cross over study where they will receive a sitagliptin pill once a day for 8
weeks and during a separate 8 weeks receive a matching placebo pill. The treatment periods
are divided by a 4 week period. Blood vessel function will be measured by ultrasound before
and after a single dose of sitagliptin and placebo, as well as after 8 weeks of treatment
with each. Blood will also be taken to measure blood markers of inflammation at each time the
ultrasounds are performed.